Collaboration for Global Impact
Strategic Partnering
We seek a mission-driven alliance. ACA Therapeutics operates under a unique Partnership-First Model. While traditional biotechs often prioritize venture capital and rapid financial exits, our focus remains steadfast on clinical success and functional restoration for all patients. We seek strategic partners, not just capital investors.
Learn More
Why Partner with ACA?
By collaborating with us, partners gain access to a de-risked, high-throughput therapeutic engine:
- Validated UMD Framework: A unique “Upstream” therapeutic model supported by 83 distinct pharmacological mechanisms and 18 Nature-family publications.
- Lead Clinical Assets: Immediate opportunity to collaborate on ACA-001 (Pancreatic Cancer), which has an approved Phase I study, and our ACA-002 (Type 2 Diabetes) program.
- Ready-to-Fire Pipeline: A robust portfolio of 10-20 Phase I Ready programs across Oncology, Neurology, and Metabolic diseases.
- Independent Capital Structure: Our programs are advanced through disciplined internal funding and established collaborative networks, ensuring we maintain long-term strategic control.
Co-Development
Shared clinical trial initiatives for our Tier 1 and Tier 2 assets.
Indication Licensing
Rights for specific indications within our 40+ therapeutic matrix.
Global Expansion
Regional alliances to deliver affordable therapies to North America, Europe, and Asia.
Mechanism Synergy
Utilizing our proprietary library to enhance existing partner pipelines.
A Scalable, Democratic Solution
We believe life-saving medicine should be accessible to all. While global capital is currently focused on high-cost, invasive therapies for the few, ACA is delivering the next generation of cost-effective, high-potency oral medicine for the people.
Transform Legacy Assets Into Next-Gen Solutions
Our validated pharmacological mechanisms re-engineer your existing molecular assets to target upstream disease drivers — extending commercial life and unlocking new indications.
Strategic Multiplier for Global Portfolios
[Technical Note for Industry Partners] Our UMD Platform acts as a strategic multiplier for global pharmaceutical portfolios. By integrating our 83 validated pharmacological mechanisms, we offer partners the unique ability to re-engineer existing molecular assets to target the “Upstream” drivers of disease.
This enables our partners to transition from traditional symptom suppression to Functional Restoration, effectively revitalizing their existing pipelines and extending the clinical and commercial impact of their core therapies. We transform “legacy assets” into next-generation “Upstream solutions.”